Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Cerveau Technologies

    Menu

    Cerveau Technologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cerveau Technologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

              Details:

              LX1001-01 (AAVrh.10hAPOE2) is an AAV-based investigational gene therapy candidate designed as a one-time treatment delivering a protective APOE2 gene into the CNS for the treatment of APOE4-associated Alzheimer’s disease.

              Lead Product(s): AAVrh.10hAPOE2

              Therapeutic Area: Neurology Product Name: LX1001

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Lexeo Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cerveau Technologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

              Details:

              The collaboration is focused on using [F-18]MK-6240 as a biomarker in neurodegenerative disease drug research and development. The companies will apply [F-18]MK-6240 imaging to evaluate Alnylam’s therapeutic ALN-APP, for the treatment of neurodegenerative diseases.

              Lead Product(s): ALN-APP

              Therapeutic Area: Neurology Product Name: ALN-APP

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY